A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Stopped early · Phase 1

Conditions studied: Advanced Solid Malignancies

In brief

The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

Key facts

Study ID

NCT00351325

Run by

Bristol-Myers Squibb

People needed

45

Starts

2007-09-01

Expected to finish

2009-03-01

Last updated by the study team

2009-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Good activity level
• Life expectancy of ≥ 6 months
• Solid tumor malignancy for which paclitaxel and carboplatin are appropriate

You may not qualify if…

• Major surgery within 4 weeks
• Any concurrent cancer
• History of autoimmune diseases
• Symptomatic bowel obstruction
• Continued use of steroids
• Symptomatic brain metastases
• Current nerve damage in fingers/toes
• Positive for HIV, hepatitis B/C
• White blood cells < 3,000
• Hemoglobin < 9
• Platelets < 100,000
• ALT/AST and/or alkaline phosphatase >= 2.5 x ULN
• Creatine > 1.5
• Prior BMS-663513

Where it is running

• University Of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States
• Magee-Womens Hospital Of Upmc — Pittsburgh, Pennsylvania, United States
• University Of Virginia — Charlottesville, Virginia, United States
• University Of Washington — Seattle, Washington, United States
• Local Institution — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.